Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma

Results of prospective trials

I. Choi, Ryuji Tanosaki, N. Uike, A. Utsunomiya, M. Tomonaga, M. Harada, T. Yamanaka, M. Kannagi, J. Okamura

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.

Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalBone Marrow Transplantation
Volume46
Issue number1
DOIs
Publication statusPublished - 2011 Jan
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Virus Diseases
Survivors
Clinical Trials

Keywords

  • adult T-cell leukemia/lymphoma
  • allogeneic hematopoietic SCT
  • HTLV-1 proviral load
  • reduced-intensity conditioning regimen

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma : Results of prospective trials. / Choi, I.; Tanosaki, Ryuji; Uike, N.; Utsunomiya, A.; Tomonaga, M.; Harada, M.; Yamanaka, T.; Kannagi, M.; Okamura, J.

In: Bone Marrow Transplantation, Vol. 46, No. 1, 01.2011, p. 116-118.

Research output: Contribution to journalArticle

Choi, I, Tanosaki, R, Uike, N, Utsunomiya, A, Tomonaga, M, Harada, M, Yamanaka, T, Kannagi, M & Okamura, J 2011, 'Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials', Bone Marrow Transplantation, vol. 46, no. 1, pp. 116-118. https://doi.org/10.1038/bmt.2010.92
Choi, I. ; Tanosaki, Ryuji ; Uike, N. ; Utsunomiya, A. ; Tomonaga, M. ; Harada, M. ; Yamanaka, T. ; Kannagi, M. ; Okamura, J. / Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma : Results of prospective trials. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 1. pp. 116-118.
@article{d38613d1edc443f4b4f4428f8c0c879b,
title = "Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials",
abstract = "We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.",
keywords = "adult T-cell leukemia/lymphoma, allogeneic hematopoietic SCT, HTLV-1 proviral load, reduced-intensity conditioning regimen",
author = "I. Choi and Ryuji Tanosaki and N. Uike and A. Utsunomiya and M. Tomonaga and M. Harada and T. Yamanaka and M. Kannagi and J. Okamura",
year = "2011",
month = "1",
doi = "10.1038/bmt.2010.92",
language = "English",
volume = "46",
pages = "116--118",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma

T2 - Results of prospective trials

AU - Choi, I.

AU - Tanosaki, Ryuji

AU - Uike, N.

AU - Utsunomiya, A.

AU - Tomonaga, M.

AU - Harada, M.

AU - Yamanaka, T.

AU - Kannagi, M.

AU - Okamura, J.

PY - 2011/1

Y1 - 2011/1

N2 - We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.

AB - We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.

KW - adult T-cell leukemia/lymphoma

KW - allogeneic hematopoietic SCT

KW - HTLV-1 proviral load

KW - reduced-intensity conditioning regimen

UR - http://www.scopus.com/inward/record.url?scp=78651371147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651371147&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.92

DO - 10.1038/bmt.2010.92

M3 - Article

VL - 46

SP - 116

EP - 118

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -